KCM
UTHR icon

Kendall Capital Management’s United Therapeutics UTHR Stock Holding History

Kendall Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Sell
5,881
-400
-6% -$225K 0.53% 48
2026
Q1 		$3.72M Sell
6,281
-278
-4% -$138K 0.76% 31
2025
Q4 		$3.2M Sell
6,559
-591
-8% -$275K 0.67% 37
2025
Q3 		$3M Sell
7,150
-30
-0.4% -$10.1K 0.68% 39
2025
Q2 		$2.06M Sell
7,180
-90
-1% -$26.9K 0.55% 52
2025
Q1 		$2.24M Buy
7,270
+475
+7% +$163K 0.66% 45
2024
Q4 		$2.4M Buy
6,795
+253
+4% +$93K 0.7% 44
2024
Q3 		$2.34M Buy
6,542
+340
+5% +$115K 0.72% 41
2024
Q2 		$1.98M Buy
6,202
+550
+10% +$146K 0.66% 45
2024
Q1 		$1.3M Buy
5,652
+1,440
+34% +$325K 0.45% 70
2023
Q4 		$926K Buy
4,212
+1,310
+45% +$302K 0.36% 91
2023
Q3 		$655K Buy
2,902
+1,557
+116% +$359K 0.29% 106
2023
Q2 		$297K Buy
+1,345
New +$298K 0.13% 160
2018
Q4 		– Sell
-1,690
Closed -$216K – 115
2018
Q3 		$216K Sell
1,690
-1,545
-48% -$191K 0.18% 104
2018
Q2 		$366K Sell
3,235
-1,275
-28% -$140K 0.32% 85
2018
Q1 		$507K Buy
4,510
+125
+3% +$15.9K 0.44% 70
2017
Q4 		$649K Buy
+4,385
New +$557K 0.58% 55

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Kendall Capital Management's UTHR Position: Q2 2026 in Review

Kendall Capital Management reduced its United Therapeutics (UTHR) stake by 6.4% in Q2 2026, selling an estimated $225K and leaving 5,881 shares worth $3.19M. The position accounts for 0.53% of the portfolio, ranked #48.

Kendall Capital Management first reported a position in UTHR in Q4 2017 and has held it in 17 quarters since. The position peaked at $3.72M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Kendall Capital Management held 5,881 shares of United Therapeutics worth $3.19M as of Q2 2026.
  • Kendall Capital Management sold 400 United Therapeutics shares in Q2 2026, an estimated $225K.
  • United Therapeutics made up 0.53% of Kendall Capital Management's portfolio in Q2 2026, its #48 holding.
  • Kendall Capital Management first reported a position in United Therapeutics in Q4 2017 and has held it in 17 quarters since.
  • Kendall Capital Management's United Therapeutics position peaked at $3.72M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Kendall Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.